COMP <GO>
CHE vs ABBV // ALTMAN Z-SCORE & DEBT/EQUITY
Chemed Corp (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: CHE 4
— ABBV 8
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: CHE
LAST: $541.92 (+1.61%) • MKT CAP: $7.08B
balance-sheet
12.68
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
balance-sheet
5.33
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CHE VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CHE | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 32.50% | 70.20% | -37.70 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 23.40% | 29.00% | -5.60 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 18.5x | 33.3x | -14.80 | CHE | /valuation <GO> |
| Free Cash Flow Yield | 4.60% | 3.47% | +1.13 | CHE | /fcf-yield <GO> |
| Operating Margin | 13.40% | 24.60% | -11.20 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 0.00% | 6.90% | -6.90 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 65.30% | 8.60% | +56.70 | CHE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.45% | 2.27% | -1.82 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 12.68 | 5.33 | +7.35 | CHE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 64.9 | 65.1 | -0.20 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 1.15 | -0.07 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.08B | $513.86B | -$506.78B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CHE REV | ABBV REV | CHE GROSS % | ABBV GROSS % | CHE FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.53B | $61.16B | 32.5% | 70.2% | $325.5M | $17.82B |
| FY 2024 | $1.53B | $56.33B | — | 70.0% | $368.0M | $17.83B |
| FY 2023 | $1.32B | $54.32B | — | — | $271.1M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CHE // BETA 1.08
ABBV // BETA 1.15